Henlius 2025 Annual Results Showcase Unprecedented Revenue and Profit Growth Amidst Global Expansion Efforts Henlius shares impressive 2025 annual results showing significant revenue growth, profit increase, and advancements in global biopharmaceutical operations.

Henlius 2025 Annual Results Showcase Unprecedented Revenue and Profit Growth Amidst Global Expansion Efforts #China #Shanghai #Serplulimab #Henlius_Biotech #HERCESSI

Accord BioPharma’s HERCESSI™ Receives Significant Formulary Status Expansion Accord BioPharma's oncology treatment HERCESSI™ has been added to Express Scripts' preferred formulary list, enhancing patient access to affordable cancer therapies.

Accord BioPharma’s HERCESSI™ Receives Significant Formulary Status Expansion #United_States #Raleigh #Accord_BioPharma #HERCESSI #HERCEPTIN